Page last updated: 2024-11-08

hetacillin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

taxiresinol: tetrahydrofuran-type lignan isolated from the wood of Taxus yunnanensis; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

taxiresinol : A lignan that consists of tetrahydrofuran substituted by a 3,4-dihydroxyphenyl group at position 2, a hydroxymethyl group at position 3 and a 4-hydroxy-3-methoxybenzyl group at position 4. It has been isolated from Taxus yunnanensis. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
TaxusgenusGenus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).[MeSH]TaxaceaeA plant family of the order Pinales, class Pinopsida, division TRACHEOPHYTA.[MeSH]

Cross-References

ID SourceID
PubMed CID10088963
CHEMBL ID1668114
CHEBI ID70197
MeSH IDM0262683
PubMed CID443387
CHEMBL ID1201116
CHEBI ID5683
SCHEMBL ID34131
MeSH IDM0262683

Synonyms (79)

Synonym
bdbm50335919
(+)-taxiresinol
taxiresinol
chebi:70197 ,
CHEMBL1668114 ,
4-[(2s,3r,4r)-4-(4-hydroxy-3-methoxybenzyl)-3-(hydroxymethyl)tetrahydrofuran-2-yl]benzene-1,2-diol
SNZZAHRDXCGWEM-CKFHNAJUSA-N
Q27138536
FS-9307
4-[(2s,3r,4r)-4-[(4-hydroxy-3-methoxyphenyl)methyl]-3-(hydroxymethyl)oxolan-2-yl]benzene-1,2-diol
4-[tetrahydro-4-[(4-hydroxy-3-methoxyphenyl)methyl]-3-hydroxymethylfuran-2-yl]-1,2-benzenediol
AKOS040760058
HY-14578
CS-0003456
hetacillin
3511-16-8
6beta-[(4r)-2,2-dimethyl-5-oxo-4-phenylimidazolidin-1-yl]penicillanic acid
(2s,5r,6r)-6-[(4r)-2,2-dimethyl-5-oxo-4-phenylimidazolidin-1-yl]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
DB00739
versapen (tn)
D01074
hetacillin (usan/inn)
versapen
etacillina [dcit]
phenazacillin
brl 804
6-(2,2-dimethyl-5-oxo-4-phenyl-1-imidazolidinyl)penicillansaeure
hetacillinum [inn-latin]
4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(2,2-dimethyl-5-oxo-4-phenyl-1-imidazolidinyl)-3,3-dimethyl-7-oxo-, (2s-(2alpha,5alpha,6beta(s*)))-
bl-p 804
(2s,%r,6r)-6-(2,2-dimethyl-5-oxo-4-phenyl-1-imidazolidinyl)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptan-2-carbonsaeure
n,n'-isopropylidene-a-amino-benzyl penicillin
6-(2,2-dimethyl-5-oxo-4-phenyl-1-imidazolidinyl)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid
einecs 222-512-5
hetacilina [inn-spanish]
hetacilline [inn-french]
hetacilline
hetacillinum
6beta-[(4r)-2,2-dimethyl-5-oxo-4-phenylimidazolidin-1-yl]-2,2-dimethylpenam-3alpha-carboxylic acid
CHEBI:5683 ,
hetacilina
hetacillin acid
bl-p-804
blp-804
CHEMBL1201116
brl-804
tn4jsc48cv ,
etacillina
unii-tn4jsc48cv
hetacillin [usan:usp:inn:ban]
6-(2,2-dimethyl-5-oxo-4-phenyl-1-imidazolidinyl)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
hetacillin [inn]
4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-((4r)-2,2-dimethyl-5-oxo-4-phenyl-1-imidazolidinyl)-3,3-dimethyl-7-oxo-, (2s,5r,6r)-
hetacillin [who-dd]
4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(2,2-dimethyl-5-oxo-4-phenyl-1-imidazolidinyl)-3,3-dimethyl-7-oxo-, (2s-(2.alpha.,5.alpha.,6.beta.(s*)))-
hetacillin [mi]
hetacillin [orange book]
hetacillin [mart.]
hetacillin [usan]
SCHEMBL34131
DXVUYOAEDJXBPY-NFFDBFGFSA-N
CS-4870
HY-16251A
DTXSID4023121 ,
AKOS027381814
(2s,5r,6r)-6-((r)-2,2-dimethyl-5-oxo-4-phenylimidazolidin-1-yl)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
7-(2,2-dimethyl-5-oxo-4-phenyl-imidazolidin-1-yl)-3,3-dimethyl-6-oxo-2-thia-5-azabicyclo[3.2.0]heptane-4-carboxylic acid
Q5746710
gtpl12263
EN300-19734686
6beta-((4r)-2,2-dimethyl-5-oxo-4-phenylimidazolidin-1-yl)-2,2-dimethylpenam-3alpha-carboxylic acid
hetacilline (inn-french)
(2s,5r,6r)-6-((4r)-2,2-dimethyl-5-oxo-4-phenylimidazolidin-1-yl)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid
hetacillin (usan:usp:inn:ban)
hetacillinum (inn-latin)
hetacilina (inn-spanish)
hetacillin (mart.)
6beta-((4r)-2,2-dimethyl-5-oxo-4-phenylimidazolidin-1-yl)penicillanic acid
dtxcid503121

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" An increasing number of dairy farms are milking 3 times per day (instead of the traditional 2 times per day) and very little pharmacokinetic data exists on the use of intramammary drugs in a 3×system."( Short communication: Pharmacokinetics of intramammary hetacillin in dairy cattle milked 3 times per day.
Baynes, RE; Lindquist, DA; Smith, GW, 2015
)
0.67

Bioavailability

The relative bioavailability of sarpicillin (the methoxymethyl ester of hetacillin) from three different oral dosage forms was compared in humans. The effect of liver enzyme induction on bioavailability was studied in patients chronically treated with anticonvulsants or chlorpromazine.

ExcerptReferenceRelevance
"The effect of liver enzyme induction on bioavailability of hetacillin was studied in patients chronically treated with anticonvulsants or chlorpromazine."( Effect of enzyme induction on bioavailability of hetacillin in patients treated with anticonvulsants and chlorpromazine.
Dimakopoulou, K; Galanopoulou, P; Karageorgiou, C,
)
0.63
"The relative bioavailability of sarpicillin (the methoxymethyl ester of hetacillin) from three different oral dosage forms was compared in humans employing a three-way crossover study design."( Evaluation of the bioavailability of sarpicillin, the methoxymethyl ester of hetacillin, in humans.
Hottendorf, GH; Martin, A; Newburger, J; Pearlman, RS; Schneider, LW; Smyth, RD; Stavchansky, S; Van Harken, DR, 1984
)
0.73

Dosage Studied

ExcerptRelevanceReference
" The method is precise, accurate and applicable to the analysis of commercial dosage form."( HPLC determination of K-hetacillin and Na-dicloxacillin in oily suspension.
Caccialanza, G; Gandini, C; Kitsos, M; Massolini, G,
)
0.44
"The relative bioavailability of sarpicillin (the methoxymethyl ester of hetacillin) from three different oral dosage forms was compared in humans employing a three-way crossover study design."( Evaluation of the bioavailability of sarpicillin, the methoxymethyl ester of hetacillin, in humans.
Hottendorf, GH; Martin, A; Newburger, J; Pearlman, RS; Schneider, LW; Smyth, RD; Stavchansky, S; Van Harken, DR, 1984
)
0.73
" Based on this study, milk ampicillin concentrations exceed the minimum inhibitory concentration required to inhibit the growth of 90% of organisms (MIC90) for at least 65% of the dosing interval, which is sufficient for once-daily dosing with most cases of gram-positive mastitis."( Short communication: Pharmacokinetics of intramammary hetacillin in dairy cattle milked 3 times per day.
Baynes, RE; Lindquist, DA; Smith, GW, 2015
)
0.67
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
antibacterial drugA drug used to treat or prevent bacterial infections.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (6)

ClassDescription
lignanAny phenylpropanoid derived from phenylalanine via dimerization of substituted cinnamic alcohols, known as monolignols, to a dibenzylbutane skeleton. Note that while individual members of the class have names ending ...lignane, ...lignene, ...lignadiene, etc., the class names lignan, neolignan, etc., do not end with an "e".
polyphenolMembers of the class of phenols that contain 2 or more benzene rings each of which is substituted by at least one hydroxy group.
tetrolA polyol that contains 4 hydroxy groups.
oxolanesAny oxacycle having an oxolane (tetrahydrofuran) skeleton.
guaiacolsAny phenol carrying an additional methoxy substituent at the ortho-position.
penicillinAny member of the group of substituted penams containing two methyl substituents at position 2, a carboxylate substituent at position 3 and a carboxamido group at position 6.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 3A4Homo sapiens (human)IC50 (µMol)85.60000.00011.753610.0000AID568746
Cytochrome P450 2D6Homo sapiens (human)IC50 (µMol)68.10000.00002.015110.0000AID568747
Type-1 angiotensin II receptorOryctolagus cuniculus (rabbit)IC50 (µMol)85.60000.00010.09130.5000AID568746
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (25)

Processvia Protein(s)Taxonomy
lipid hydroxylationCytochrome P450 3A4Homo sapiens (human)
lipid metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid catabolic processCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid metabolic processCytochrome P450 3A4Homo sapiens (human)
cholesterol metabolic processCytochrome P450 3A4Homo sapiens (human)
androgen metabolic processCytochrome P450 3A4Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A4Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A4Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 3A4Homo sapiens (human)
calcitriol biosynthetic process from calciolCytochrome P450 3A4Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D metabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D catabolic processCytochrome P450 3A4Homo sapiens (human)
retinol metabolic processCytochrome P450 3A4Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A4Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 3A4Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A4Homo sapiens (human)
oxidative demethylationCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2D6Homo sapiens (human)
steroid metabolic processCytochrome P450 2D6Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2D6Homo sapiens (human)
estrogen metabolic processCytochrome P450 2D6Homo sapiens (human)
coumarin metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid catabolic processCytochrome P450 2D6Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2D6Homo sapiens (human)
isoquinoline alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2D6Homo sapiens (human)
retinol metabolic processCytochrome P450 2D6Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2D6Homo sapiens (human)
negative regulation of bindingCytochrome P450 2D6Homo sapiens (human)
oxidative demethylationCytochrome P450 2D6Homo sapiens (human)
negative regulation of cellular organofluorine metabolic processCytochrome P450 2D6Homo sapiens (human)
arachidonic acid metabolic processCytochrome P450 2D6Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (24)

Processvia Protein(s)Taxonomy
monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
steroid bindingCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 3A4Homo sapiens (human)
protein bindingCytochrome P450 3A4Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A4Homo sapiens (human)
oxygen bindingCytochrome P450 3A4Homo sapiens (human)
enzyme bindingCytochrome P450 3A4Homo sapiens (human)
heme bindingCytochrome P450 3A4Homo sapiens (human)
vitamin D3 25-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
caffeine oxidase activityCytochrome P450 3A4Homo sapiens (human)
quinine 3-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
aromatase activityCytochrome P450 3A4Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
monooxygenase activityCytochrome P450 2D6Homo sapiens (human)
iron ion bindingCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activityCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2D6Homo sapiens (human)
heme bindingCytochrome P450 2D6Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (5)

Processvia Protein(s)Taxonomy
cytoplasmCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A4Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A4Homo sapiens (human)
mitochondrionCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulumCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2D6Homo sapiens (human)
cytoplasmCytochrome P450 2D6Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2D6Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (31)

Assay IDTitleYearJournalArticle
AID568746Inhibition of CYP3A4 after 30 mins by fluorometric assay2011Journal of natural products, Jan-28, Volume: 74, Issue:1
Cytochrome P450 3A4 inhibitory constituents of the wood of Taxus yunnanensis.
AID568747Inhibition of CYP2D6 after 30 mins by fluorometric assay2011Journal of natural products, Jan-28, Volume: 74, Issue:1
Cytochrome P450 3A4 inhibitory constituents of the wood of Taxus yunnanensis.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1136664Antibacterial activity against Streptococcus pneumoniae 9585 by two-fold serial dilution technique1978Journal of medicinal chemistry, Feb, Volume: 21, Issue:2
Hetacillin (R)- and (S)-sulfoxides. Synthesis and structure-activity relationships.
AID1136670Antibacterial activity against Proteus vulgaris 9716 by two-fold serial dilution technique1978Journal of medicinal chemistry, Feb, Volume: 21, Issue:2
Hetacillin (R)- and (S)-sulfoxides. Synthesis and structure-activity relationships.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1136671Antibacterial activity against Streptococcus pyogenes A9604 infected in mouse assessed as mouse survival administered intramuscularly at 1 hr post-infection measured for 5 days1978Journal of medicinal chemistry, Feb, Volume: 21, Issue:2
Hetacillin (R)- and (S)-sulfoxides. Synthesis and structure-activity relationships.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1136669Antibacterial activity against Proteus mirabilis 9900 by two-fold serial dilution technique1978Journal of medicinal chemistry, Feb, Volume: 21, Issue:2
Hetacillin (R)- and (S)-sulfoxides. Synthesis and structure-activity relationships.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1136666Antibacterial activity against Staphylococcus aureus 9537 by two-fold serial dilution technique1978Journal of medicinal chemistry, Feb, Volume: 21, Issue:2
Hetacillin (R)- and (S)-sulfoxides. Synthesis and structure-activity relationships.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1136667Antibacterial activity against penicillin-resistant Staphylococcus aureus 9606 by two-fold serial dilution technique1978Journal of medicinal chemistry, Feb, Volume: 21, Issue:2
Hetacillin (R)- and (S)-sulfoxides. Synthesis and structure-activity relationships.
AID1136665Antibacterial activity against Streptococcus pyogenes 9604 by two-fold serial dilution technique1978Journal of medicinal chemistry, Feb, Volume: 21, Issue:2
Hetacillin (R)- and (S)-sulfoxides. Synthesis and structure-activity relationships.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1136668Antibacterial activity against Escherichia coli 15119 by two-fold serial dilution technique1978Journal of medicinal chemistry, Feb, Volume: 21, Issue:2
Hetacillin (R)- and (S)-sulfoxides. Synthesis and structure-activity relationships.
AID1136672Antibacterial activity against Streptococcus pyogenes A9604 infected in po dosed mouse assessed as mouse survival administered at 3.5 hrs post-infection measured for 5 days1978Journal of medicinal chemistry, Feb, Volume: 21, Issue:2
Hetacillin (R)- and (S)-sulfoxides. Synthesis and structure-activity relationships.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (18)

TimeframeStudies, This Drug (%)All Drugs %
pre-19909 (50.00)18.7374
1990's0 (0.00)18.2507
2000's6 (33.33)29.6817
2010's3 (16.67)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 31.42

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index31.42 (24.57)
Research Supply Index2.83 (2.92)
Research Growth Index4.59 (4.65)
Search Engine Demand Index39.34 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (31.42)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies1 (6.25%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
Other15 (93.75%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]